Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Asparagine,Gemcitabine,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ERYTECH Announces a Poster Presentation for TRYbeCA1 at the ASCO 2020
Details : ERYTECH Announces a Poster Presentation for TRYbeCA1 at the ASCO 2020 Nasdaq:ERYP.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 24, 2020
Lead Product(s) : Asparagine,Gemcitabine,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable